Hyderabad’s HITEX Exhibition Centre became the focal point for South Asia’s laboratory technology, biotechnology, analytical testing, and diagnostic industries between September 10 and 12, 2026, as analytica Lab India 2026 opened its doors to more than 400 exhibiting companies. Co-organized by the Indian Analytical Instruments Association (IAIA) and Messe München, with on-ground management by Messe Muenchen India Pvt. Ltd., the event drew industry executives, regulatory scientists, commercial trade delegations, and institutional buyers to five fully occupied exhibition halls.
The three-day fair arrived at a pivotal moment for the subcontinent’s life sciences sector. Indian pharmaceutical manufacturing is shifting away from high-volume, low-margin small-molecule generics and toward complex formulations, biosimilars, synthetic peptides, and advanced biologics — a transition that has brought tighter regulatory scrutiny in its wake. Global health authorities, including the US FDA, the European Medicines Agency, and the World Health Organization, are maintaining close oversight of data integrity, electronic audit trails, and ultra-trace impurity detection, particularly around Nitrosamine Drug Substance-Related Impurities (NDSRIs).
Against that backdrop, analytica Lab India 2026 functioned as more than a commercial trade fair. Its opening session, held on the morning of September 10 and led into by a traditional lamp-lighting ceremony, brought together state policymakers, international diplomats, trade envoys, and pharmaceutical leaders to address how public policy, foreign trade, and private capital are reshaping South Asia’s scientific ecosystem.
Telangana’s Bid for a Global Life Sciences Hub
Sarvesh Singh, Director and Chief Executive Officer of Telangana Lifesciences (Government of Telangana), delivered the opening policy address, situating the state’s life sciences strategy within broader macroeconomic goals. Singh pointed to Hyderabad’s emergence as a life sciences center anchored by the Genome Valley cluster, large-scale manufacturing corridors, and specialized biotechnology incubators, noting that the region produces roughly one-third of the world’s vaccine supply and a major share of India’s bulk drug and finished generic exports.
Sustaining that growth, Singh said, requires a shift from production volume to high-value manufacturing. He outlined state government investment directed toward advanced bioprocessing, novel therapeutic modalities, contract research infrastructure, and digitalized R&D labs intended to help the regional cluster move into higher-margin scientific services.
The Compliance Mandate: Automation and Zero-Defect QA/QC
Madan Mohan Reddy, Whole-Time Director of Aurobindo Pharma, addressed the operational realities facing Indian drugmakers operating across hundreds of export markets under continuous regulatory oversight. Analytical laboratories, he argued, can no longer function as isolated, end-of-line verification units. The industry’s move toward complex formulations, liposomal preparations, and bio-macromolecules demands analytical instrumentation capable of sub-part-per-billion detection limits, automated workflows that minimize human sampling error, and computerized systems that generate unalterable audit trails. Reddy described high-precision instrumentation and lab automation as essential investments for maintaining GxP compliance across international supply chains.
Germany and Türkiye Deepen Bilateral Ties
The diplomatic presence at the opening session underscored the cross-border nature of scientific supply chains. Amita Desai, Honorary Consul and Head of Mission of the Federal Republic of Germany in Hyderabad, spoke to the deep technological ties between German engineering and Indian pharmaceutical manufacturing, noting that the analytica trade fair itself originated in Munich. She pointed to Hyderabad — home to one of the largest concentrations of German Academic Exchange Service (DAAD) alumni — as a natural hub for expanded Indo-German partnerships in precision instrumentation, specialized reagents, and automated laboratory infrastructure.
Tuğçe Gül, Commercial Attaché at the Consulate General of the Republic of Türkiye in Hyderabad, discussed the growing trade relationship between India and Türkiye, now worth nearly $7.5 billion. She outlined initiatives aimed at linking Turkish producers of specialty chemicals, mineral derivatives, and diagnostic products with Indian pharmaceutical manufacturers, and described the trade floor as a venue for joint ventures in diagnostics, scientific equipment, and high-purity process chemicals.
Formulation Science and the Sustainability Mandate
K. V. Rambabu, Managing Director of Pulse Pharmaceuticals and Chairman of the Telangana State Board of the Indian Drug Manufacturers’ Association, addressed the integration of formulation design with specialized testing methods, arguing that delivery platforms such as lipid nanoparticles, targeted release formulations, and fixed-dose combinations demand closer collaboration between formulation teams and analytical method developers.
Dr. Pravin Khullar, President of the Goa Pharmaceutical Manufacturers’ Association, turned attention to the industry’s environmental footprint, noting that pharmaceutical manufacturing accounts for roughly 5% of global greenhouse gas emissions. He called on laboratories to adopt “sustainability by design” through reduced hazardous solvent use, energy-efficient instrumentation, and a “7 Rs” operational model — reduce, reuse, recycle, redesign, repair, recover, and remanufacture — adding that AI and IoT-based monitoring can optimize testing runs while curbing material waste.
Domestic Manufacturing and the IAIA’s Self-Reliance Push
Ravindranath Cherukuri, President of the Indian Analytical Instruments Association, highlighted the growing capabilities of domestic instrument manufacturers, who are moving beyond basic benchtop equipment into hybrid chromatography columns, automated extraction stations, gas generation systems, and specialized sample-prep hardware. He argued that domestic manufacturing reduces import exposure, shortens service turnaround times, and delivers cost-effective testing tools tailored to local generic and contract-testing operations.
Avisha Desai, Executive Director at Messe Muenchen India, closed the opening remarks by framing the trade platform’s strategic role: connecting international engineering firms directly with Indian pharmaceutical and biotechnology centers, turning the exhibition into an active venue for capital investment, technology transfer, and long-term procurement agreements.
